<DOC>
	<DOC>NCT01364623</DOC>
	<brief_summary>The purpose of this study is to assess the bioavailability of total testosterone through pharmacokinetic profiles obtained following (a) single administration of three doses of TBS-2 b) multiple administration TBS-2. In addition, assessing the bioavailability of free testosterone, dihydrotestosterone, SHBG and estradiol through pharmacokinetic profiles will also be conducted.</brief_summary>
	<brief_title>PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women</brief_title>
	<detailed_description>This is a 2 Period study that requires overnight stays in clinic. Blood samples are required at all visits including sampling at predefined time periods during the overnight stays. Period I Subjects will be checked-in on Day 1 Period I to start their baseline testosterone measurement (dependant on menstrual cycle, preferably within 48hr of start of the menstrual cycle). They will remain institutionalized until Day 4 morning, and will be checked out after the 48 hour blood draw and study close-out for those that do not continue with Period II. Period II (Multi-Dose) Subjects will be institutionalized starting on Day 1 of Visit 3 until Day 5 morning of Visit 3, and will be checked out after the 48 hour blood draw and study close-out.</detailed_description>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria Subjects having regular menstrual cycles between 2632 days. Women of childbearing potential must agree to use one of the following reliable birth control methods prior to the study, during the study and up until one month after the end of the study: Surgically sterile Intrauterine device in place for at least 3 months prior to study initiation Barrier method (condom with spermicidal agent use by partner) Abstinence Negative for drugs of abuse, hepatitis Bsurface antigen, hepatitis C, HIV, and pregnancy (serum ßHCG). Body Mass Index greater than or equal to 18.5 kg/m² and less than or equal to 35 kg/m². Subjects with a normal ENT exam. Subjects with normal TSH values. No clinically significant findings in the physical examination, 12lead ECG and vital signs Normal thyroid function. Physiological prolactin concentration. All clinical laboratory test values within the acceptable ranges (any clinically significant findings will require investigator/sponsor approval) Able to understand and provide written informed consent. Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed ICF Exclusion Criteria Known history of hypersensitivity to Testosterone (e.g. Intrinsa patch) and/or related drugs. Known history of polycystic ovarian syndrome. Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, psychiatric, hematological, reproductive, liver or kidney disease, unless judged not clinically significant by the Principal Investigator or medical designate. Presence of or known history of Estrogenresponsive tumors such as breast cancer and /or history of any cancer, excluding basal cell carcinoma. Known history of frequent clinically significant acne. Known history of hirsutism History of nasal surgery, specifically turbinoplasty, septoplasty, rhinoplasty, "nose job", or sinus surgery. Prior nasal fractures. Active allergies, such as rhinitis, rhinorrhea, and nasal congestion. Mucosal inflammatory disorders, specifically pemphigus, and Sjogren's syndrome. Sinus disease, specifically acute sinusitis, chronic sinusitis, or allergic fungal sinusitis. History of nasal disorders or sleep apnea. Use of any form of intranasal medication delivery, specifically nasal corticosteroids and oxymetazoline containing nasal sprays History of Hepatitis B, a positive test for Hepatitis B surface antigen, a history of Hepatitis C, a positive test for Hepatitis C antibody, a history of HIV infection or demonstration of HIV antibodies. Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs. Any history of drug abuse or alcohol abuse as per DSMIV criteria within 6 months of study drug administration. Current treatment with any hormone replacement therapy within previous 12 months, treatment with drugs which interfere with metabolism of Testosterone within 30 days of study drug administration and/or any other prescription medications. Difficulty in abstaining from OTC medication for the duration of study. Use of oral, transdermal and implant contraceptives within 30 days prior to drug administration or a depot contraceptives injection within one year prior to drug administration. Evidence of pregnancy or lactation. Subjects who are breast feeding or have breast fed within the last six (6) months prior to the Screening Visit. Administration of another investigational drug within 30 days prior to study medication administration. Blood donation within 56 days prior to study medication administration. Any participation as a plasma donor in a plasmapheresis program within seven days preceding screening in this study. Intolerance to venipuncture. History of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture or intravenous cannulation. History of Deep Venous Thrombosis or coagulation disorders.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>testosterone</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>